Art. -Nr.: HY-B0097

Floxuridine

(Synonyms: 5-Fluorouracil 2'-deoxyriboside)

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis. Floxuridine has antiviral effects against HSV and CMV.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 50-91-9
Formel: C₉H₁₁FN₂O₅
Molecular Weight:246.19

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Floxuridine Chemical Structure

CAS. Nr.: 50-91-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis^[1]^[2]. Floxuridine has antiviral effects against HSV and CMV^[3].

IC₅₀ & Target^[1]^[2]^[3]

DNA synthesis

Bacterial

HSV

CMV

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle HSV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
143B	CC₅₀	9.5 x 10^-5 M Compound: FUDR	In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line) In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)	[PMID: 12620076]
143B	CC₅₀	0.0001 M Compound: FUDR	In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK	[PMID: 12620076]
143B	CC₅₀	0.1 mM Compound: FUDR	In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK	[PMID: 12620076]
143B	IC₅₀	14.1 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
143B	IC₅₀	6.02 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human 143B cells after 72 hrs by SRB assay Cytotoxicity against human 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
791T cell line	IC₅₀	0.8 μg/mL Compound: 5-FdUR	Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression	[PMID: 8496926]
791T cell line	IC₅₀	3.2 μM Compound: 5-FdUR	Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression	[PMID: 8496926]
A2780	IC₅₀	0.026 μM Compound: FdUrd	Cytotoxicity against human A2780 cells after 5 days by MTT assay Cytotoxicity against human A2780 cells after 5 days by MTT assay	[PMID: 22738636]
A549	EC₅₀	9.74 μM Compound: Floxuridine	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19917528]
A549	IC₅₀	0.047 μM Compound: 5-FdUrd	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by WST-8 assay	[PMID: 22248856]
A549	IC₅₀	0.0124 μM Compound: 5-FdUrd	Cytotoxicity against human A549 cells after 72 hrs by microplate reader method Cytotoxicity against human A549 cells after 72 hrs by microplate reader method	[PMID: 22847019]
A549	EC₅₀	60.8 μM Compound: 5; FDU; Floxuridine	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
A549	IC₅₀	5.91 μM Compound: 2; FdU	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	5.8 μM Compound: Floxuridine	Cytotoxicity against human A549 cells assessed as reduction in cell viability at 100 uM by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability at 100 uM by MTT assay	[PMID: 34147747]
A549	IC₅₀	>100 μM Compound: FdUR	Cytotoxicity against human A549 cells after 24 hrs measured by MTT assay Cytotoxicity against human A549 cells after 24 hrs measured by MTT assay	[PMID: 34734726]
A549	IC₅₀	>100 μM Compound: FdUR	Cytotoxicity against human A549 cells after 48 hrs measured by MTT assay Cytotoxicity against human A549 cells after 48 hrs measured by MTT assay	[PMID: 34734726]
A549	IC₅₀	1 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung. Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.	10.1016/0960-894X(96)00339-3
ACHN	GI₅₀	2.1 μM Compound: Floxuridine	Anticancer activity against human ACHN cells by SRB assay Anticancer activity against human ACHN cells by SRB assay	[PMID: 20732810]
AZ-521 cell line	IC₅₀	0.05 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of AZ-521 tumor cell line from stomach. Compound was tested for its inhibitory effect on the growth of AZ-521 tumor cell line from stomach.	10.1016/0960-894X(96)00339-3
BALB/3T3	IC₅₀	23.9 μM Compound: FdU	Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
C170	IC₅₀	0.1 μg/mL Compound: 5-FdUR	Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro	[PMID: 8496926]
C170	IC₅₀	0.4 μM Compound: 5-FdUR	Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro Tested for cytotoxicity against C170 colorectal carcinoma cell line by [75Se]selenomethionine uptake assay, in vitro	[PMID: 8496926]
Caco-2	IC₅₀	12.85 μM Compound: FdU	Antiproliferative activity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human Caco2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
CCRF-CEM	IC₅₀	0.0003 μg/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0) Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0)	[PMID: 11123990]
CCRF-CEM	IC₅₀	0.3 ng/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0) Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (CEM/0)	[PMID: 11123990]
CCRF-CEM	GI₅₀	0.002 μM Compound: FUdR	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	GI₅₀	0.0006 μM Compound: FUdR	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	GI₅₀	0.6 nM Compound: FUdR	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	IC₅₀	0.5 μM Compound: FUDR	Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119) Tested in vitro for the inhibition of cell growth of human T lymphoblastoid CCRF-CEM cell line (ATCC CCL 119)	[PMID: 11909716]
CCRF-CEM	IC₅₀	0.29 μM Compound: FUdR	Cytostatic activity against human CCRFCEM cells by MTT assay Cytostatic activity against human CCRFCEM cells by MTT assay	[PMID: 17804231]
CCRF-CEM	IC₅₀	0.017 μM Compound: FUdR	Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs Cytostatic activity against human CCRF-CEM cells ATCC CCL 119 assessed as growth reduction after 72 hrs	[PMID: 17997319]
CCRF-CEM	IC₅₀	0.017 μM Compound: FUdR	Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs Cytostatic activity in human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs	[PMID: 18078757]
CCRF-CEM	IC₅₀	0.022 μM Compound: 2, FUDR	Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.04 μM Compound: 2, FUDR	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.8 μM Compound: 2, FUDR	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR	[PMID: 21892829]
CCRF-CEM	IC₅₀	1.36 μM Compound: 2, FUDR	Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole	[PMID: 21892829]
CCRF-CEM	IC₅₀	2.5 μM Compound: 2, FUDR	Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	3 μM Compound: 2, FUDR	Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting	[PMID: 21892829]
CCRF-CEM	IC₅₀	0.002 μM Compound: 2	In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM). In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).	[PMID: 8917645]
CEM-TK(+)	IC₅₀	66.3 μM Compound: 2	In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line (CEM-TK) In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line (CEM-TK)	[PMID: 8917645]
COLO 320DM	IC₅₀	0.65 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of COLO 320DM tumor cell line from colon. Compound was tested for its inhibitory effect on the growth of COLO 320DM tumor cell line from colon.	10.1016/0960-894X(96)00339-3
COS-7	IC₅₀	>1000 μM Compound: 2'-deoxy-5-fluorouridine	Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake in presence of Na+ by liquid scintillation counting method Inhibition of human CNT2 expressed in COS7 cells assessed as reduction in sodium-dependent [14C]-inosine uptake in presence of Na+ by liquid scintillation counting method	[PMID: 25815140]
DLD-1	IC₅₀	0.092 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of DLD-1 tumor cell line from colon. Compound was tested for its inhibitory effect on the growth of DLD-1 tumor cell line from colon.	10.1016/0960-894X(96)00339-3
FM3A	IC₅₀	0.0008 μg/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0) Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0)	[PMID: 11123990]
FM3A	IC₅₀	0.8 ng/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0) Evaluated for the inhibition of tumor cell growth of murine mammary carcinoma malignant tumor cell line (FM3A/0)	[PMID: 11123990]
FM3A	IC₅₀	0.0094 μM Compound: 5-FdUrd	Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis Cytostatic activity against mouse FM3A cells after 2 days by coulter counting analysis	[PMID: 21330014]
HCT-15	IC₅₀	0.049 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of HCT-15 tumor cell line from colon. Compound was tested for its inhibitory effect on the growth of HCT-15 tumor cell line from colon.	10.1016/0960-894X(96)00339-3
HCT-8	EC₅₀	0.015 μM Compound: Floxuridine	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 29469575]
HEK-293T	CC₅₀	0.0084 μM Compound: Floxuridine	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HeLa	IC₅₀	>25 μM Compound: FUDR	Tested in vitro for the inhibition of cell growth of human cervix carcinoma HeLa S3 cell (ATCC CCL 2.2) Tested in vitro for the inhibition of cell growth of human cervix carcinoma HeLa S3 cell (ATCC CCL 2.2)	[PMID: 11909716]
HeLa	EC₅₀	10.26 μM Compound: Floxuridine	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19917528]
HeLa	IC₅₀	0.021 μM Compound: 5-FdUrd	Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine Cytostatic activity against human HeLa cells in presence of 20 uM 2'-deoxyuridine	[PMID: 21330014]
HeLa	IC₅₀	0.061 μM Compound: 5-FdUrd	Cytostatic activity against human HeLa cells in presence of 500 uM uridine Cytostatic activity against human HeLa cells in presence of 500 uM uridine	[PMID: 21330014]
HeLa	IC₅₀	0.11 μM Compound: 5-FdUrd	Cytostatic activity against human HeLa cells in presence of 500 uM uracil Cytostatic activity against human HeLa cells in presence of 500 uM uracil	[PMID: 21330014]
HeLa	IC₅₀	8.5 μM Compound: 5-FdUrd	Cytostatic activity against human HeLa cells in presence of 20 uM thymidine Cytostatic activity against human HeLa cells in presence of 20 uM thymidine	[PMID: 21330014]
HeLa	IC₅₀	0.05 μM Compound: 2, FUDR	Cytostatic activity against human HeLa cells after 72 hrs by cell counting Cytostatic activity against human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
HeLa	IC₅₀	1.4 μM Compound: 2, FUDR	Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting	[PMID: 21892829]
HeLa	IC₅₀	6.5 μM Compound: 1, FdU, floxuridine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 23867603]
HeLa	IC₅₀	5.31 μM Compound: FdU	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
HeLa	IC₅₀	6.5 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27073055]
HeLa	IC₅₀	6.5 μM Compound: FdU	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	IC₅₀	6.5 μM Compound: 2; FdU	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	EC₅₀	18.84 μM Compound: Floxuridine	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 19917528]
HepG2	IC₅₀	8.91 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 27073055]
HepG2	IC₅₀	8.91 μM Compound: FdU	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HepG2	CC₅₀	76 μM Compound: Floxuridine	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HepG2	IC₅₀	8.91 μM Compound: 2; FdU	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HFF	EC₅₀	0.91 μM Compound: FUDR	Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	0.96 μM Compound: FUDR	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	1.13 μM Compound: FUDR	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HFF	EC₅₀	1.19 μM Compound: FUDR	Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay	[PMID: 17698618]
HL-60	IC₅₀	0.012 μM Compound: FUdR	Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs Cytostatic activity against human HL60 cells ATCC CCL 240 assessed as growth reduction after 72 hrs	[PMID: 17997319]
HL-60	IC₅₀	0.012 μM Compound: FUdR	Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs Cytostatic activity in human HL60 cells assessed as inhibition of cell growth after 72 hrs	[PMID: 18078757]
HL-60	IC₅₀	0.24 μM Compound: FdU	Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 25644674]
HT-1080	IC₅₀	0.18 μM Compound: FUdR	Cytostatic activity against human HT1080 cells by MTT assay Cytostatic activity against human HT1080 cells by MTT assay	[PMID: 17804231]
HT-1080	IC₅₀	0.12 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of HT1080 sarcoma tumor cell line. Compound was tested for its inhibitory effect on the growth of HT1080 sarcoma tumor cell line.	10.1016/0960-894X(96)00339-3
HT-29	IC₅₀	115.12 μM Compound: FdU	Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human HT-29 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
Huh-7	CC₅₀	>813 μM Compound: 27	Cytotoxicity against HuH7 cells Cytotoxicity against HuH7 cells	[PMID: 20857959]
Jurkat	EC₅₀	0.00333 μM Compound: 5; FDU; Floxuridine	Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
KB	IC₅₀	8.69 μM Compound: 1, FdU, floxuridine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 23867603]
KB	IC₅₀	8.69 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 27073055]
KB	IC₅₀	8.69 μM Compound: FdU	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	8.69 μM Compound: 2; FdU	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KBALB-STK	CC₅₀	8.8 x 10^-11 M Compound: FUDR	In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK	[PMID: 12620076]
KBALB-STK	CC₅₀	0.0001 M Compound: FUDR	In vitro cell cytotoxicity was determined against KBALB-STK cell line In vitro cell cytotoxicity was determined against KBALB-STK cell line	[PMID: 15027876]
KBALB-STK	CC₅₀	0.1 mM Compound: FUDR	In vitro cell cytotoxicity was determined against KBALB-STK cell line In vitro cell cytotoxicity was determined against KBALB-STK cell line	[PMID: 15027876]
KKLS	IC₅₀	0.76 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of KKLS tumor cell line from stomach. Compound was tested for its inhibitory effect on the growth of KKLS tumor cell line from stomach.	10.1016/0960-894X(96)00339-3
L1210	IC₅₀	0.0003 μg/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0) Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0)	[PMID: 11123990]
L1210	IC₅₀	0.3 ng/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0) Evaluated for the inhibition of tumor cell growth of murine leukemia malignant tumor cell line (L1210/0)	[PMID: 11123990]
L1210	IC₅₀	0.64 nM Compound: FUdR	Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment Growth inhibition in L1210 mouse leukemia cells after 48 hr treatment	[PMID: 11728193]
L1210	IC₅₀	23 nM Compound: FUdR	Growth inhibition in L1210 mouse leukemia cells after 8 h treatment Growth inhibition in L1210 mouse leukemia cells after 8 h treatment	[PMID: 11728193]
L1210	IC₅₀	4.1 nM Compound: FUdR	Growth inhibition in L1210 mouse leukemia cells after 24 h treatment Growth inhibition in L1210 mouse leukemia cells after 24 h treatment	[PMID: 11728193]
L1210	IC₅₀	45 nM Compound: FUdR	Growth inhibition in L1210 mouse leukemia cells after 2 hr treatment Growth inhibition in L1210 mouse leukemia cells after 2 hr treatment	[PMID: 11728193]
L1210	IC₅₀	7.9 nM Compound: FUdR	Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment Thymidylate synthase inhibition in L1210 mouse leukemia cells after 2 hr treatment	[PMID: 11728193]
L1210	IC₅₀	<0.02 μM Compound: FUDR	Tested in vitro for the inhibition of cell growth of mouse leukemia L1210 cell (ATCC CCL 219) Tested in vitro for the inhibition of cell growth of mouse leukemia L1210 cell (ATCC CCL 219)	[PMID: 11909716]
L1210	IC₅₀	0.012 μM Compound: FUdR	Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs Cytostatic activity against mouse L1210 cells ATCC CCL219 assessed as growth reduction after 72 hrs	[PMID: 17997319]
L1210	IC₅₀	0.012 μM Compound: FUdR	Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs Cytostatic activity in mouse L1210 cells assessed as inhibition of cell growth after 72 hrs	[PMID: 18078757]
L1210	IC₅₀	0.0004 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 4 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 4 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.0006 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 15 mins by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.0007 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 4 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 4 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.0011 μM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis Cytostatic activity against mouse L1210 cells after 2 days by coulter counting analysis	[PMID: 21330014]
L1210	IC₅₀	0.0023 μM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine Cytostatic activity against mouse L1210 cells in presence of 500 uM uridine	[PMID: 21330014]
L1210	IC₅₀	0.0051 μM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine Cytostatic activity against mouse L1210 cells in presence of 20 uM 2'-deoxyuridine	[PMID: 21330014]
L1210	IC₅₀	100 μM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine Cytostatic activity against mouse L1210 cells in presence of 20 uM thymidine	[PMID: 21330014]
L1210	IC₅₀	0.0004 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.0006 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.00063 μM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil	[PMID: 21330014]
L1210	IC₅₀	0.0007 μM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.4 nM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxyuridine after preincubation for 24 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.6 nM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 15 mins by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.63 nM Compound: 5-FdUrd	Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil Cytostatic activity against mouse L1210 cells in presence of 500 uM uracil	[PMID: 21330014]
L1210	IC₅₀	0.7 nM Compound: 5-FdUrd	Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting Inhibition of thymidylate synthase in mouse L1210 cells assessed as inhibition of tritium release from [5-3H]deoxycytidine after preincubation for 24 hrs by liquid scintillation counting	[PMID: 21330014]
L1210	IC₅₀	0.34 μM Compound: 2, FUDR	Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]
L1210	IC₅₀	3 μM Compound: 2, FUDR	Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting	[PMID: 21892829]
L1210	IC₅₀	5.0 x 10^-5 M Compound: FdUrd	In vitro concentration required for 50% inhibition (IC50) of growth of L1210 mouse leukemia cells in culture. In vitro concentration required for 50% inhibition (IC50) of growth of L1210 mouse leukemia cells in culture.	[PMID: 6228661]
L1210	IC₅₀	0.012 μM Compound: 2	In vitro cytotoxicity of compounds were determined on murine leukemia cell line (L1210). In vitro cytotoxicity of compounds were determined on murine leukemia cell line (L1210).	[PMID: 8917645]
L5178Y	IC₅₀	0.002 μM Compound: FdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells In vitro growth inhibition of L5178Y-Parental murine leukemia cells	[PMID: 11101356]
L5178Y	IC₅₀	0.002 μM Compound: FdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd. In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]-Thd.	[PMID: 11101356]
L5178Y	IC₅₀	0.0024 μM Compound: FdUrd	In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu. In vitro growth inhibition of L5178Y-Parental murine leukemia cells by incorporation of [14C]Leu.	[PMID: 11101356]
L5178Y	IC₅₀	0.13 μM Compound: FdUrd	In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Thd. In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Thd.	[PMID: 11101356]
L5178Y	IC₅₀	0.14 μM Compound: FdUrd	In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells	[PMID: 11101356]
L5178Y	IC₅₀	0.15 μM Compound: FdUrd	In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Leu. In vitro growth inhibition of FdUrd resistant L5178Y-Resistant murine leukemia cells by incorporation of [14C]Leu.	[PMID: 11101356]
L5178Y	IC₅₀	0.76 nM Compound: FdUrd	Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition) Comparative inhibition of L5178Y cell growth in vitro (concentration required for 50% inhibition)	[PMID: 6779007]
L929	IC₅₀	>25 μM Compound: FUDR	Tested in vitro for the inhibition of cell growth of murine L929 cells (ATCC CCL 1) Tested in vitro for the inhibition of cell growth of murine L929 cells (ATCC CCL 1)	[PMID: 11909716]
L929	IC₅₀	7.7 μM Compound: 2	In vitro cytotoxicity of compounds were determined on mouse fibroblast (L929 TK-). In vitro cytotoxicity of compounds were determined on mouse fibroblast (L929 TK-).	[PMID: 8917645]
Lewis lung carcinoma cell line	IC₅₀	14.2 μM Compound: 5-FDU	Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay Cytotoxicity against mouse LLC cells after 24 hrs by resazurin assay	[PMID: 21536448]
Lewis lung carcinoma cell line	IC₅₀	2 μM Compound: 5-FDU	Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay Cytotoxicity against mouse LLC cells after 72 hrs by resazurin assay	[PMID: 21536448]
LM	IC₅₀	260 nM Compound: FUdR	Thymidylate synthase inhibition in wild type LM cells after 2 hr treatment Thymidylate synthase inhibition in wild type LM cells after 2 hr treatment	[PMID: 11728193]
LM	IC₅₀	5400 nM Compound: FUdR	Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment Thymidylate synthase inhibition in thymidine kinase deficient LM cells after 2 hr treatment	[PMID: 11728193]
LNCaP	IC₅₀	69.2 nM Compound: FudR	Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells Cytotoxic concentration in prostate specific antigen (PSA) producing human LNCaP cells	[PMID: 12161157]
LoVo	IC₅₀	19.07 μM Compound: FdU	Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
LS180	IC₅₀	140.28 μM Compound: FdU	Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method Antiproliferative activity against human LS180 cells assessed as growth inhibition after 72 hrs by SRB method	[PMID: 25644674]
MCF7	IC₅₀	12.19 μM Compound: 1, FdU, floxuridine	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23867603]
MCF7	IC₅₀	12.19 μM Compound: 1; FdU; floxuridine	Cytotoxicity against human MCF7cells after 72 hrs by SRB assay Cytotoxicity against human MCF7cells after 72 hrs by SRB assay	[PMID: 27073055]
MCF7	IC₅₀	12.19 μM Compound: FdU	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	>100 μM Compound: FdUR	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 24 hrs by MTT assay	[PMID: 34734726]
MCF7	IC₅₀	46.94 μM Compound: FdUR	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation measured after 48 hrs by MTT assay	[PMID: 34734726]
MDA-MB-231	IC₅₀	0.21 μM Compound: 1, 5-FUd	Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator Cytotoxicity against human MDA-MB-231 cells overexpressing urokinase plasminogen activator	[PMID: 20363130]
MDA-MB-231	GI₅₀	0.16 μM Compound: Floxuridine	Anticancer activity against human MDA-MB-231 cells by SRB assay Anticancer activity against human MDA-MB-231 cells by SRB assay	[PMID: 20732810]
MDA-MB-231	GI₅₀	35.1 mM Compound: FUdR	Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 32882127]
MDA-MB-231	IC₅₀	38 μM Compound: Floxuridine	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 100 uM by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 100 uM by MTT assay	[PMID: 34147747]
MDA-MB-468	IC₅₀	27.42 μM Compound: Floxuridine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MDA-MB-468	IC₅₀	45.53 μM Compound: Floxuridine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MIA PaCa-2	GI₅₀	27.3 mM Compound: FUdR	Antiproliferative activity against human MIA-PaCa-2 cells assessed as growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MIA-PaCa-2 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 32882127]
MKN-28	IC₅₀	0.12 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of MKN-28 tumor cell line from stomach. Compound was tested for its inhibitory effect on the growth of MKN-28 tumor cell line from stomach.	10.1016/0960-894X(96)00339-3
MKN-45	IC₅₀	3.5 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of MKN-45 tumor cell line from stomach. Compound was tested for its inhibitory effect on the growth of MKN-45 tumor cell line from stomach.	10.1016/0960-894X(96)00339-3
MOLT-4	IC₅₀	2.6 μg/mL Compound: 5-FdUrd	Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (Molt4/C8) Evaluated for the inhibition of tumor cell growth of Human T-Lymphocyte cells (Molt4/C8)	[PMID: 11123990]
MRC5	IC₅₀	22.46 μM Compound: FdU	Antiproliferative activity against human MRC5 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human MRC5 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
NHDF	IC₅₀	13.05 μM Compound: FdU	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	13.05 μM Compound: 2; FdU	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
NUGC-3	IC₅₀	0.015 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of NUGC-3 tumor cell line from stomach. Compound was tested for its inhibitory effect on the growth of NUGC-3 tumor cell line from stomach.	10.1016/0960-894X(96)00339-3
PANC-1	IC₅₀	>40 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of PANC-1 tumor cell line from pancreas. Compound was tested for its inhibitory effect on the growth of PANC-1 tumor cell line from pancreas.	10.1016/0960-894X(96)00339-3
PC-3	GI₅₀	4.97 μM Compound: Floxuridine	Anticancer activity against human PC3 cells by SRB assay Anticancer activity against human PC3 cells by SRB assay	[PMID: 20732810]
PC-3	EC₅₀	86.9 μM Compound: 5; FDU; Floxuridine	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
PRK	IC₅₀	>400 μg/mL Compound: 5-F-2'-d Urd	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [Me-3H]-dThd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [Me-3H]-dThd	[PMID: 6267280]
PRK	IC₅₀	1 μg/mL Compound: 5-F-2'-d Urd	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary Rabbit by 50% Concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary Rabbit by 50%	[PMID: 6267280]
PRK	IC₅₀	10 μg/mL Compound: 5-F-2'-d Urd	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [1,'2'-3H]dUrd Concentration required to reduce HSV-1(KOS) induced cytopathogenicity primary rabbit kidney by 50% was measured by the addition of [1,'2'-3H]dUrd	[PMID: 6267280]
Ramos	EC₅₀	0.00751 μM Compound: 5; FDU; Floxuridine	Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human Ramos cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
RAW264.7	IC₅₀	30 μM Compound: 5-FDU	Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay Cytotoxicity against mouse RAW264.7 cells after 72 hrs by resazurin assay	[PMID: 21536448]
SNU-C2A	IC₅₀	0.0033 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of SUN-C2A tumor cell line from colon. Compound was tested for its inhibitory effect on the growth of SUN-C2A tumor cell line from colon.	10.1016/0960-894X(96)00339-3
SW48	IC₅₀	0.13 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of SW-48 tumor cell line from colon. Compound was tested for its inhibitory effect on the growth of SW-48 tumor cell line from colon.	10.1016/0960-894X(96)00339-3
SW-620	IC₅₀	0.96 μM Compound: Floxuridine	Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
SW-620	IC₅₀	1.48 μM Compound: Floxuridine	Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
T-24	IC₅₀	1 μg/mL Compound: 5-FdUR	Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression	[PMID: 8496926]
T-24	IC₅₀	4.1 μM Compound: 5-FdUR	Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression Tested for cytotoxicity against antigen negative T-24 bladder carcinoma cells having only 3-5% antigen expression	[PMID: 8496926]
T-24	IC₅₀	0.12 μM Compound: FdUrd (2'-deoxy-5-fluorouridine)	Compound was tested for its inhibitory effect on the growth of T24 tumor cell line from bladder. Compound was tested for its inhibitory effect on the growth of T24 tumor cell line from bladder.	10.1016/0960-894X(96)00339-3
T47D	IC₅₀	5.61 μM Compound: FdU	Antiproliferative activity against human T47D cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human T47D cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
T98G	IC₅₀	5.57 μM Compound: FdU	Antiproliferative activity against human T98G cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human T98G cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
TSU	IC₅₀	58 nM Compound: FudR	Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells Cytotoxic concentration in non prostate specific antigen (PSA) producing human TSU cells	[PMID: 12161157]
U-118-MG	IC₅₀	23.4 μM Compound: FdU	Antiproliferative activity against human U118MG cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human U118MG cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
U-87MG ATCC	IC₅₀	10.37 μM Compound: FdU	Antiproliferative activity against human U87MG cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human U87MG cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26994842]
U-87MG ATCC	EC₅₀	18.2 μM Compound: 5; FDU; Floxuridine	Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay	[PMID: 27032331]
U-87MG ATCC	IC₅₀	6.14 μM Compound: 2; FdU	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
WI-38	IC₅₀	500 μM Compound: FUdR	Cytostatic activity against human WI38 cells MTT assay Cytostatic activity against human WI38 cells MTT assay	[PMID: 17804231]
ZR-75-1	GI₅₀	30.1 mM Compound: FUdR	Antiproliferative activity against human ZR-75-1 cells assessed as growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human ZR-75-1 cells assessed as growth inhibition after 24 hrs by MTT assay	[PMID: 32882127]

In Vitro

Floxuridine (0-25 μM; 4-24 hours) is affectd by inhibitors of PARP and its sensitivity of ovarian cancer cells is enhanced. Co-exposed to FdUrd and the PARP inhibitor markedly increases killing cell numbers when its compare to treatment alone in ovarian cancer cells^[1].
Floxuridine (300 μM; 4-24 hours) increases p-Chk1 and p-Chk2 in ovarian cancer cell lines. It may induce DNA damage and activate the ATM and ATR checkpoint signaling pathways^[1].
Floxuridine (0-2.5 μM; 24 hours) causes a G1/S-phase arrest and following removal of the FdUrd, the G1/S-phase-arrested cells moved synchronously through S phase and into G2/M^[1].
Floxuridine is also a very potent inhibitor of staphylococcal growth (MIC, 0.025–0.00313 μM)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Ovarian cancer cells
Concentration:

0-25 μM
Incubation Time:

4, 8, 24 hours
Result:

Was potentiated the sensitivity by PARP inhibitors.

Western Blot Analysis^[1]

Cell Line:

OVCAR-8 and SKOV3ip cells
Concentration:

300 μM
Incubation Time:

4, 8, 24 hours
Result:

Induced phosphorylation of Chk1 and Chk2 in two ovarian cancer cell lines

Cell Cycle Analysis^[1]

Cell Line:

A2780, SKOV3ip, OVCAR-5, and OVCAR-3 ovarian cancer cells
Concentration:

0.5, 1.0, 1.5, 2.0, and 2.5 μM
Incubation Time:

24 hours
Result:

Induced cell arrest at G1/S-phase period.

In Vivo

Floxuridine (intraperitoneal injection; 0.5-1.25 mg/kg; once per day for 7 days or single dose) is sufficient to show statistically significant protection against S. aureus infection at 0.5 mg/kg for 7 days. In addition, 1.25 mg/kg single administration of the compound shows statistically significant protection against S. aureus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice injected with S. aureus^[2]
Dosage:

0.5-1.25 mg/kg
Administration:

once per day for 7 days or single dose
Result:

Was a very potent inhibitor for S. aureus infection in vivo.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 50-91-9
Appearance Solid
Molecular Weight 246.19
Formel C₉H₁₁FN₂O₅
Color White to off-white
SMILES

OC[C@@H]1[C@@H](O)C[C@H](N2C(NC(C(F)=C2)=O)=O)O1
Synonyms

5-Fluorouracil 2'-deoxyriboside
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All WBCell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

Gip1 GPCR regulates two sexual-stage differentiation processes in the ascomycete Fusarium graminearum. [Abstract]

2025 Jul 8;16(1):6279. PMID: 40628729
Neuron

DCPS modulates TDP-43-linked neurodegeneration through P-body-mediated RNA decay. [Abstract]

2026 Mar 9:S0896-6273(26)00044-9. PMID: 41943580
Sci Adv

Tandem repeat-induced sexual silencing: A Rid-dependent RNAi mechanism for fungal genome defense via translational repression. [Abstract]

2025 Aug 22;11(34):eadu7606. PMID: 40834073
Small

DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment. [Abstract]

2022 Jul;18(30):e2202337. PMID: 35780479

Floxuridine purchased from MedChemExpress. Usage Cited in: Small. 2022 Jul;18(30):e2202337. [Abstract]

Cellular viability study of WELL5 cells treated with MTX, FUDR, MTX/FUDR mixture, M:F NPs, and CCNPs for 48 h.

Floxuridine purchased from MedChemExpress. Usage Cited in: Small. 2022 Jul;18(30):e2202337. [Abstract]

Flow cytometry-based apoptosis analyses of WELL5 cells treated with PBS, MTX/FUDR mixture, M:F NPs, and CCNPs for 48 h. The numbers in the images indicated the percentage of cells presented in the corresponding quadrant.

Floxuridine purchased from MedChemExpress. Usage Cited in: Small. 2022 Jul;18(30):e2202337. [Abstract]

Western blot analysis of apoptosis-associated proteins and PI3K/AKT/mTOR pathway-related key proteins in WELL5 cells treated with PBS, MTX/FUDR mixture, M:F NPs, and CCNPs for 48 h.
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Nat Struct Mol Biol

Integrator subunit INTS12 links ribotoxic stress to transcription-coupled nucleotide excision repair. [Abstract]

2026 Feb 26. PMID: 41748916
Sci Data

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]

2024 Sep 19;11(1):1024. PMID: 39300112
Stress Biol

Hyphal editing of the conserved premature stop codon in CHE1 is stimulated by oxidative stress in Fusarium graminearum. [Abstract]

2024 Jun 12;4(1):30. PMID: 38864932
Breast Cancer Res

NOTCH1 inhibition enhances immunogenicity and sensitizes triple-negative breast cancer to immune checkpoint inhibitors. [Abstract]

2025 May 26;27(1):92. PMID: 40420289

Floxuridine purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2025 May 26;27(1):92. [Abstract]

The protein expression levels of ATM, p-ATM and p-Rb was shown by western blot in shCtrl and shNOTCH1 MDA-MB-231 cells treated with Floxuridine (10 μM).

Floxuridine purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2025 May 26;27(1):92. [Abstract]

The surface expression of CALR was determined by FACS in shCtrl and shNOTCH1 MDA-MB-231 cells treated with Floxuridine (10 μM).

Floxuridine purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2025 May 26;27(1):92. [Abstract]

Tumor-free survival curves of BALB/c mice vaccinated with freeze-thawed or DAPT or Floxuridine (30 μM) treated 4T1-NICD cells (n = 10).
Int Immunopharmacol

Inhibitors of APE1 redox and ATM synergistically sensitize osteosarcoma cells to ionizing radiation by inducing ferroptosis. [Abstract]

2024 Jul 19:139:112672. PMID: 39032469

Floxuridine purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Jul 19:139:112672. [Abstract]

The protein levels of APE1, ATM and p-ATMS1981 in U2OS and 143b cells after 24 h of DMSO (Con) and ATM agonist (floxuridine, 10 μM, 24 h) treatment.
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Virology

5-Bromo-2'-deoxyuridine inhibits African swine fever virus (ASFV) replication via interfering viral DNA replication and suppressing the formation of viral factories. [Abstract]

2024 Sep 12:600:110237. PMID: 39288610
bioRxiv

2026 Apr 3.
bioRxiv

2026 Mar 9.
bioRxiv

2025 Sep 21.
bioRxiv

2023 Oct 19.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 125 mg/mL (507.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (203.09 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0618 mL

20.3092 mL

40.6184 mL

5 mM

0.8124 mL

4.0618 mL

8.1237 mL

10 mM

0.4062 mL

2.0309 mL

4.0618 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (406.18 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Huehls AM, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.Cancer Res. 2011 Jul 15;71(14):4944-54. [Content Brief]

[2]. Yeo WS, et al. The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus.Sci Rep. 2018 Feb 6;8(1):2521. [Content Brief]

[3]. Langman J, et al. Floxuridine and its influence on postnatal cerebellar development. Pediatr Res. 1972 Oct;6(10):758-64. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	4.0618 mL	20.3092 mL	40.6184 mL	101.5459 mL
	5 mM	0.8124 mL	4.0618 mL	8.1237 mL	20.3092 mL
	10 mM	0.4062 mL	2.0309 mL	4.0618 mL	10.1546 mL
	15 mM	0.2708 mL	1.3539 mL	2.7079 mL	6.7697 mL
	20 mM	0.2031 mL	1.0155 mL	2.0309 mL	5.0773 mL
	25 mM	0.1625 mL	0.8124 mL	1.6247 mL	4.0618 mL
	30 mM	0.1354 mL	0.6770 mL	1.3539 mL	3.3849 mL
	40 mM	0.1015 mL	0.5077 mL	1.0155 mL	2.5386 mL
	50 mM	0.0812 mL	0.4062 mL	0.8124 mL	2.0309 mL
	60 mM	0.0677 mL	0.3385 mL	0.6770 mL	1.6924 mL
	80 mM	0.0508 mL	0.2539 mL	0.5077 mL	1.2693 mL
	100 mM	0.0406 mL	0.2031 mL	0.4062 mL	1.0155 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Floxuridine

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Floxuridine

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Liver Cancer Compound Library

Chemotherapy Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Floxuridine

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle HSV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Floxuridine Related Classifications

Art. -Nr.: HY-B0097